Loading...
Search Filters
Date Range
toReport Types
Region of the Body
Specialties
See all (18)
Emerging Treatments
OE Recommends Topics
Multimedia
Journal
Conference Series
Evidence Series
Showing 1 - 9 of 9
Ifosfamide-based chemotherapy yields high survival rate for treatment of osteosarcoma
Drug Des Devel Ther. 2015 Nov 4;9:5925-32
Osteosarcoma: 25 year survival rate significantly improved with adjuvant chemotherapy
Cancer. 2012 Dec 1;118(23):5888-93
MTP-PE added to chemotherapy did not improve outcomes in metastatic osteosarcoma patients
Cancer. 2009 Nov 15;115(22):5339-48. doi: 10.1002/cncr.24566
Muramyl tripeptide in chemotherapy improves overall osteosarcoma survival
J Clin Oncol. 2008 Feb 1;26(4):633-8. doi: 10.1200/JCO.2008.14.0095
Osteosarcoma: methotrexate & doxorubicin versus methotrexate, etoposide & ifosfamide
Eur J Cancer. 2007 Mar;43(4):752-61. Epub 2007 Jan 30
Ifosfamide not necessary in chemotherapy for nonmetastatic osteosarcoma
J Clin Oncol. 2012 Jun 10;30(17):2112-8. doi: 10.1200/JCO.2011.38.4420. Epub 2012 May 7
Palonosetron vs. Granisetron for Chemotherapy-Induced Nausea and Vomiting in Pediatric Osteosacroma
Adv Clin Exp Med. 2022 01-Mar;():. 10.17219/acem/142332
Showing 1 - 9 of 9